Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6010 plus enlonesutamab in recurrent or metastatic head and neck squamous cell carcinoma
CTR20254625Phase 2Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CPO301, enlonesutamab in head and neck squamous cell carcinoma (HNSCC), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Dec 2025; status: active.
02
Drugs
CPO301enlonesutamab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20254625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254625.